Recombinant Anti-CD55 x Anti-HLA-A Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-CD55 specificity or anti-HLA-A specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb can recruit complements to tumor cells. It is designed for the research of Renal cell cancer (RCC); Solid tumors therapy.
scFv-based Bispecific Fragments
FuncS; Promising therapeutic agent
Renal cell cancer (RCC); Solid tumors
CD55; CD55 molecule, decay accelerating factor for complement (Cromer blood group); CR; TC; DAF; CROM; complement decay-accelerating factor; CD55 antigen
HLA-A; major histocompatibility complex, class I, A; HLAA; HLA class I histocompatibility antigen, A-1 alpha chain; antigen presenting molecule; leukocyte antigen class I-A; MHC class I antigen HLA-A heavy chain
Our services and products are only for lab research, not for any diagnostic or therapeutic use.
Welcome! For price inquiries, we will get back to you as soon as possible.
To order, please email